ATE537811T1 - Stabile nicht wässerige einphasige visköse vehikel und formulierungen die diese vehikel verwenden - Google Patents

Stabile nicht wässerige einphasige visköse vehikel und formulierungen die diese vehikel verwenden

Info

Publication number
ATE537811T1
ATE537811T1 AT06075430T AT06075430T ATE537811T1 AT E537811 T1 ATE537811 T1 AT E537811T1 AT 06075430 T AT06075430 T AT 06075430T AT 06075430 T AT06075430 T AT 06075430T AT E537811 T1 ATE537811 T1 AT E537811T1
Authority
AT
Austria
Prior art keywords
vehicles
formulations
stable non
aqueous single
phase viscous
Prior art date
Application number
AT06075430T
Other languages
English (en)
Inventor
Stephan Berry
Pamela J Fereira
Houdin Dehnad
Anna Muchnik
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22382917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE537811(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Application granted granted Critical
Publication of ATE537811T1 publication Critical patent/ATE537811T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT06075430T 1999-02-08 2000-02-02 Stabile nicht wässerige einphasige visköse vehikel und formulierungen die diese vehikel verwenden ATE537811T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11917099P 1999-02-08 1999-02-08

Publications (1)

Publication Number Publication Date
ATE537811T1 true ATE537811T1 (de) 2012-01-15

Family

ID=22382917

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00913350T ATE322889T1 (de) 1999-02-08 2000-02-02 Stabile nicht wässerige einphasige visköse vehikeln und formulierungen die diese vehikeln verwenden
AT06075430T ATE537811T1 (de) 1999-02-08 2000-02-02 Stabile nicht wässerige einphasige visköse vehikel und formulierungen die diese vehikel verwenden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00913350T ATE322889T1 (de) 1999-02-08 2000-02-02 Stabile nicht wässerige einphasige visköse vehikeln und formulierungen die diese vehikeln verwenden

Country Status (22)

Country Link
EP (2) EP1666026B2 (de)
JP (1) JP4861551B2 (de)
KR (2) KR20080045300A (de)
CN (1) CN1232244C (de)
AR (1) AR029613A1 (de)
AT (2) ATE322889T1 (de)
AU (1) AU775904B2 (de)
CA (1) CA2361424C (de)
CO (1) CO5140096A1 (de)
CY (1) CY1119950T1 (de)
DE (1) DE60027272T2 (de)
DK (1) DK1666026T4 (de)
ES (2) ES2379471T5 (de)
HK (1) HK1041451B (de)
HU (1) HUP0200202A3 (de)
IL (1) IL144755A0 (de)
NO (1) NO20013861L (de)
NZ (1) NZ513441A (de)
PT (2) PT1152749E (de)
TW (2) TWI292716B (de)
WO (1) WO2000045790A2 (de)
ZA (1) ZA200106443B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1578398A2 (de) * 2002-12-19 2005-09-28 ALZA Corporation Stabilisierte nicht-wässrige einphasige gele und diese enthaltende zusammensetzungen zur verabreichung aus einer implantierbaren vorrichtung
CA2520610A1 (en) 2003-03-31 2004-10-21 Alza Corporation Osmotic pump with means for dissipating internal pressure
BRPI0408925A (pt) * 2003-03-31 2006-04-04 Alza Corp veìculos de fase simples não-aquosos e formulações utilizando tais veìculos
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
JP2008528698A (ja) 2005-02-03 2008-07-31 インターシア セラピューティクス，インコーポレイティド 埋め込み可能なインターフェロン含有デバイス
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (de) 2010-10-20 2012-04-25 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen
EP2462921A1 (de) 2010-11-11 2012-06-13 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2714010B1 (de) 2011-05-25 2017-03-01 Novaliq GmbH Topische pharmazeutische zusammensetzung auf der basis von semifluorierten alkanen
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
CA2853112C (en) 2011-10-25 2018-08-21 Onclave Therapeutics Limited Antibody formulations and methods
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
CN113662929A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
ES2819005T3 (es) 2016-12-23 2021-04-14 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
EP3612228B1 (de) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Jodzusammensetzungen
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
EP3784246A1 (de) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmische zusammensetzungen mit tafluprost zur behandlung von glaukomen
ES2950878T3 (es) 2018-09-27 2023-10-16 Dermaliq Therapeutics Inc Formulación de protección solar de uso tópico
EP3856124A1 (de) 2018-09-27 2021-08-04 Novaliq GmbH Reparatur von lipidbarrieren
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
EP3923907B1 (de) 2019-02-13 2024-09-25 Novaliq GmbH Zusammensetzungen und verfahren zur behandlung von okularer neovaskularisation
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
WO2025056807A1 (en) * 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) † 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
JPS5788115A (en) * 1980-10-06 1982-06-01 Miles Lab Stable non-aqueous solution of tetracycline antibiotic salt
DE3320583A1 (de) † 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPS61189230A (ja) * 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd エトポシド製剤
GB8528959D0 (en) * 1985-11-25 1986-01-02 Leo Pharm Prod Ltd Chemical compounds
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
JPH0720866B2 (ja) † 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
JP2794022B2 (ja) † 1988-11-11 1998-09-03 三生製薬株式会社 ブナゾシン或いはその塩類含有経皮適用製剤
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
JPH03236317A (ja) † 1989-12-06 1991-10-22 Sansei Seiyaku Kk ドパミン誘導体含有経皮用製剤
US5733572A (en) † 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
EP0520119A1 (de) † 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
WO1993009763A1 (en) † 1991-11-15 1993-05-27 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5314685A (en) † 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
AU6410494A (en) 1993-03-17 1994-10-11 Alza Corporation Device for the transdermal administration of alprazolam
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
EP0705097B2 (de) † 1993-06-25 2004-01-14 Alza Corporation Einarbeitung eines poly-n-vinylamids in ein transdermales system
EP0721349A1 (de) 1993-09-29 1996-07-17 Alza Corporation Hautpermeabilitäterhöher für oxybutynin bestehend aus monoglycerid/laktat estern
US5869088A (en) * 1994-10-24 1999-02-09 Nikken Chemicals Co., Ltd Transdermal administration preparation of a 9-aminocyclopenta (b) quinoline
US5736159A (en) † 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
DE69624354T2 (de) * 1995-06-06 2003-06-05 F. Hoffmann-La Roche Ag, Basel Pharmazeutische zusammensetzung enthaltend einen inhibitor von proteinase und einen monoglycerid
DK0836506T4 (da) † 1995-06-07 2012-01-30 Ortho Mcneil Pharm Inc Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6572879B1 (en) † 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5906830A (en) † 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5766620A (en) † 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
ES2259746T3 (es) † 1996-07-15 2006-10-16 Alza Corporation Nuevas formulaciones para la administracion transdermica de fluoxetina.
AU4990797A (en) † 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
DE19646392A1 (de) † 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
JP2002512597A (ja) 1996-12-20 2002-04-23 アルザ コーポレイション 注射可能な貯留槽ゲル組成物およびこの組成物の製造方法
US20020039594A1 (en) † 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
SI9700186B (sl) † 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin

Also Published As

Publication number Publication date
CN1232244C (zh) 2005-12-21
HUP0200202A2 (hu) 2002-05-29
HK1041451A1 (en) 2002-07-12
AR029613A1 (es) 2003-07-10
DE60027272D1 (de) 2006-05-24
WO2000045790A3 (en) 2000-12-07
DK1666026T4 (da) 2015-05-04
NZ513441A (en) 2004-01-30
CY1119950T1 (el) 2018-12-12
EP1666026B1 (de) 2011-12-21
ATE322889T1 (de) 2006-04-15
EP1666026A3 (de) 2007-08-08
JP2002536315A (ja) 2002-10-29
EP1152749B1 (de) 2006-04-12
KR100858856B1 (ko) 2008-09-17
EP1666026B2 (de) 2015-02-25
PT1666026E (pt) 2012-03-15
ES2379471T3 (es) 2012-04-26
IL144755A0 (en) 2002-06-30
HK1094528A1 (en) 2007-04-04
NO20013861L (no) 2001-09-20
NO20013861D0 (no) 2001-08-08
EP1666026A2 (de) 2006-06-07
ZA200106443B (en) 2002-08-06
CN1339962A (zh) 2002-03-13
PT1152749E (pt) 2006-08-31
CA2361424A1 (en) 2000-08-10
HK1041451B (en) 2006-12-01
TW200730199A (en) 2007-08-16
AU3481600A (en) 2000-08-25
HUP0200202A3 (en) 2009-08-28
ES2379471T5 (es) 2015-05-26
EP1152749A2 (de) 2001-11-14
ES2261190T3 (es) 2006-11-16
CO5140096A1 (es) 2002-03-22
TWI292716B (en) 2008-01-21
CA2361424C (en) 2009-04-28
DE60027272T2 (de) 2007-01-25
JP4861551B2 (ja) 2012-01-25
KR20080045300A (ko) 2008-05-22
DK1666026T3 (da) 2012-04-10
WO2000045790A2 (en) 2000-08-10
KR20010101842A (ko) 2001-11-14
AU775904B2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
ATE322889T1 (de) Stabile nicht wässerige einphasige visköse vehikeln und formulierungen die diese vehikeln verwenden
ATE404175T1 (de) Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
DE60008533D1 (de) Stabile magnetorheologische flüssigkeiten
ATE306928T1 (de) Fulvestrant formulierung
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240L (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
ATE226088T1 (de) Stabile insulinformulierungen
PT1130966E (pt) Formulacoes antiparasitarias
DE60043817D1 (de) Stickstoff enthaltende veresterte carboxylatinterpd schmiermittel diese enthaltend
PT1237408E (pt) Formulacoes para derramar
DE50101916D1 (de) Flüssige formulierungen
IS6398A (is) Lyfjablöndur
DE60000804D1 (de) Stabile mikrobizide Formulierung
DK1283051T3 (da) Stabile insulinformuleringer
DE60024476D1 (de) Pedikulizide und veterinärmedizinische zusammensetzungen
FI991487A0 (fi) Liikuteltava röntgenlaite
DE59900656D1 (de) Mischvorrichtung
NO990730L (no) Mekanisk blandeanordning
NO20005029D0 (no) Teleskopisk anordning
EP1222913A4 (de) Enthaarungsmittel und wirkstoffe zur externen anwendung
NO20014366D0 (no) Kosmetikkstiftblanding
ATE231982T1 (de) Verteilervorrichtung